losartan has been researched along with Camurati-Engelmann Disease in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Camurati-Engelmann Disease (CED) is a rare sclerosing bone disease, sometimes associated delayed puberty." | 6.82 | Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature. ( Cui, L; Guan, W; Jiang, Y; Li, Q; Li, X; Xia, W; Yu, W, 2022) |
| "Treatment with losartan was initiated at a daily dose of 0." | 5.40 | Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. ( Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014) |
| "Camurati-Engelmann Disease (CED) is a rare sclerosing bone disease, sometimes associated delayed puberty." | 2.82 | Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature. ( Cui, L; Guan, W; Jiang, Y; Li, Q; Li, X; Xia, W; Yu, W, 2022) |
| "Camurati-Engelmann disease or progressive diaphyseal dysplasia is a rare autosomal dominant sclerosing bone dysplasia." | 2.61 | Camurati-Engelmann Disease. ( Boudin, E; Mortier, G; Van Hul, W; Vanhoenacker, FM, 2019) |
| "Camurati-Engelmann disease (CED) is a rare autosomal dominant disease." | 1.91 | Proband and the Brother. ( B, S; Kotha, JP, 2023) |
| "Camurati-Engelmann disease is an extremely rare disease characterized by hyperostosis of multiple long bones." | 1.48 | Clinical characteristics and treatment outcomes in Camurati-Engelmann disease: A case series. ( Choi, JH; Kang, E; Kim, GH; Kim, YM; Lee, BH; Yoo, HW, 2018) |
| " The boy underwent an experimental treatment with losartan at a dosage of 50 mg/day, orally." | 1.40 | Positive effects of an angiotensin II type 1 receptor antagonist in Camurati-Engelmann disease: a single case observation. ( Boduroglu, K; Bonafe, L; Campos-Xavier, B; Dikoglu, E; Simsek-Kiper, PO; Superti-Furga, A; Unger, S; Utine, GE, 2014) |
| "Treatment with losartan was initiated at a daily dose of 0." | 1.40 | Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. ( Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, L | 1 |
| Li, Q | 1 |
| Guan, W | 1 |
| Yu, W | 1 |
| Li, X | 1 |
| Xia, W | 1 |
| Jiang, Y | 1 |
| B, S | 1 |
| Kotha, JP | 1 |
| Wahba, Y | 1 |
| Abdel Ghaffar, NA | 1 |
| Shaltout, A | 1 |
| Elsharkawy, A | 1 |
| Combier, A | 1 |
| Palazzo, E | 1 |
| Forien, M | 1 |
| Gardette, A | 1 |
| Dieudé, P | 1 |
| Ottaviani, S | 1 |
| Kim, YM | 1 |
| Kang, E | 1 |
| Choi, JH | 1 |
| Kim, GH | 1 |
| Yoo, HW | 1 |
| Lee, BH | 1 |
| Van Hul, W | 1 |
| Boudin, E | 1 |
| Vanhoenacker, FM | 1 |
| Mortier, G | 1 |
| Simsek-Kiper, PO | 1 |
| Dikoglu, E | 1 |
| Campos-Xavier, B | 1 |
| Utine, GE | 1 |
| Bonafe, L | 1 |
| Unger, S | 1 |
| Boduroglu, K | 1 |
| Superti-Furga, A | 1 |
| Ayyavoo, A | 1 |
| Derraik, JG | 1 |
| Cutfield, WS | 1 |
| Hofman, PL | 1 |
3 reviews available for losartan and Camurati-Engelmann Disease
| Article | Year |
|---|---|
Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature.
Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bone Density | 2022 |
Failure of conventional treatment and losartan in Camurati-Engelmann disease: A case report.
Topics: Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Camurati-Engelmann Syndrome; Drug Therap | 2018 |
Camurati-Engelmann Disease.
Topics: Adrenal Cortex Hormones; Bone and Bones; Camurati-Engelmann Syndrome; Cell Proliferation; Diagnosis, | 2019 |
5 other studies available for losartan and Camurati-Engelmann Disease
| Article | Year |
|---|---|
Proband and the Brother.
Topics: Adult; Camurati-Engelmann Syndrome; Child; Female; Humans; Losartan; Male; Mutation; Pain; Positron | 2023 |
Camurati-Engelmann disease: New clinical insights in an Egyptian case report.
Topics: Bone and Bones; Camurati-Engelmann Syndrome; Child, Preschool; Egypt; Female; Humans; Losartan; Pain | 2020 |
Clinical characteristics and treatment outcomes in Camurati-Engelmann disease: A case series.
Topics: Adolescent; Adrenal Cortex Hormones; Camurati-Engelmann Syndrome; Child; Child, Preschool; Female; H | 2018 |
Positive effects of an angiotensin II type 1 receptor antagonist in Camurati-Engelmann disease: a single case observation.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Camurati-Engelmann Syndrome; Humans; Losartan; | 2014 |
Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Camurati-Engelmann Syndrome; Child; Exercise; Female; Human | 2014 |